Business
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimensAccelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR M
About this update from Molecular Partners Ag
[{"type":"image","alt":"Molecular Partners","displaySize":"","headline":null,"caption":"Molecular Partners","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_O68YKj8eCWCeSjo6zZBpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTk4O2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/81b364e4c3e34884b6ba113a6f539ffa","width":300,"height":70}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimens","length":95,"tagName":"p"}]},{"val":[{"type":"text","content":"Accelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure ","length":100,"tagName":"p"}]},{"val":[{"type":"text","content":"Six of eight responders presented with low bone marrow blast counts at baseline, supporting further investigation in this patient population most likely to benefit from MP0533","length":175,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":370,"olType":false},{"type":"text","content":"ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), has today announced it will present updated data from a Phase 1/2a trial of the multispecific T-cell engager MP0533 in patients with acute myeloid leukemia (AML) in a poster at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 6-9, 2025, in Orlando, Florida.","length":639,"tagName":"p"},{"type":"text","content":"The poster outlines the latest results of this multicenter, open-label study evaluating MP0533 for the treatment of patients with relapsed/refractory (R/R) AML and myelodysplastic syndrome (MDS)/AML (ClinicalTrials.gov: NCT05673057). Data from cohorts 8 and 9 show that densified MP0533 dosing appears tolerable and leads to markedly improved serum exposure in treatment cycle 1, with encouraging preliminary antitumor activity.","length":428,"tagName":"p"},{"type":"text","content":"“The res...